Komori
Management planning197ATAUNS Laboratories,Inc.Pharmaceuticals

(Correction) Notice concerning a partial correction to the "Notice concerning the update to the Medium-Term Management Plan"

The displayed full-year operating profit forecast for the fiscal year ending June 2026 on page 6 of the attached materials has been corrected from ¥4.4 billion (¥4,368 million) to ¥4.3 billion (¥4,368 million). The actual amount of ¥4,368 million and the content of the full-year earnings forecast and medium-term management plan remain unchanged.

Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
1
¥100 million (difference in displayed amount)
Wording
Definitive
How definitive the wording is.

The document this correction applies to

Timely disclosure
Notice Regarding the Update to the Medium-Term Management Plan2026-07-15

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure15 July 2026

Notice Regarding the Update to the Medium-Term Management Plan

Open the original document
9 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-07-24
Location of correction (where in the original document)

Part of the description on page 6 of the attached materials, “Factors Behind Changes in Operating Profit from the Fiscal Year Ending June 2026 to the Fiscal Year Ending June 2031”

Before correction

¥4.4 billion (¥4,368 million)

After correction

¥4.3 billion (¥4,368 million)

ChangesDecrease of ¥100 million as displayed (¥4,368 million unchanged)
Impact on Business Performance (the company’s explanation)

There is no change to the full-year earnings forecast for the fiscal year ending June 2026 or to the content of the medium-term management plan.

Reason for correction

Because the displayed figures used a mixture of rounding and truncation, the presentation has been standardized to truncation.

What was corrected and how
ItemDetails
Disclosure subject to correctionNotice Regarding the Update to the Medium-Term Management Plan
Original disclosure date15 July 2026
Location of correctionPart of the description on page 6 of the attached materials, “Factors Behind Changes in Operating Profit from the Fiscal Year Ending June 2026 to the Fiscal Year Ending June 2031”
Details of correction¥4.4 billion (¥4,368 million) → ¥4.3 billion (¥4,368 million)
Reason for correctionBecause the displayed figures used a mixture of rounding and truncation, the presentation has been standardized to truncation.
Impact on Business PerformanceThere is no change to the full-year earnings forecast for the fiscal year ending June 2026 or to the content of the medium-term management plan.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the displayed figures used a mixture of rounding and truncation, the presentation has been standardized to truncation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Notice concerning a partial correction to the "Notice concerning the update to the Medium-Term Management Plan" | TAUNS Laboratories,Inc. (197A) timely disclosure | Komori